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haBACKGROUND The risk-beneﬁt ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for
prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial ﬁbrillation (NVAF) requires
continued evaluation.
OBJECTIVES This study sought to assess composite data regarding left atrial appendage closure (LAAC) in 2 ran-
domized trials compared to warfarin for prevention of stroke, systemic embolism, and cardiovascular death in patients
with nonvalvular AF.
METHODS Our meta-analysis included 2,406 patients with 5,931 patient-years (PY) of follow-up from the PROTECT AF
(Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) and PREVAIL
(Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long
Term Warfarin Therapy) trials, and their respective registries (Continued Access to PROTECT AF registry and Continued
Access to PREVAIL registry).
RESULTS With mean follow-up of 2.69 years, patients receiving LAAC with the Watchman device had signiﬁcantly fewer
hemorrhagic strokes (0.15 vs. 0.96 events/100 patient-years [PY]; hazard ratio [HR]: 0.22; p ¼ 0.004), cardiovascular/
unexplained death (1.1 vs. 2.3 events/100 PY; HR: 0.48; p ¼ 0.006), and nonprocedural bleeding (6.0% vs. 11.3%; HR:
0.51; p ¼ 0.006) compared with warfarin. All-cause stroke or systemic embolism was similar between both strategies
(1.75 vs. 1.87 events/100 PY; HR: 1.02; 95% CI: 0.62 to 1.7; p ¼ 0.94). There were more ischemic strokes in the device
group (1.6 vs. 0.9 and 0.2 vs. 1.0 events/100 PY; HR: 1.95 and 0.22, respectively; p ¼ 0.05 and 0.004, respectively).
Both trials and registries identiﬁed similar event rates and consistent device effect in multiple subsets.
CONCLUSIONS In patients with NVAF at increased risk for stroke or bleeding who are candidates for chronic antico-
agulation, LAAC resulted in improved rates of hemorrhagic stroke, cardiovascular/unexplained death, and nonprocedural
bleeding compared to warfarin. (J Am Coll Cardiol 2015;65:2614–23) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CV = cardiovascular
HR = hazard ratio
INR = international normalized
ratio
LAA = left atrial appendage
LAAC = left atrial appendage
closure
NOAC = new oral
anticoagulant agent
NVAF = nonvalvular atrial
ﬁbrillation
PY = patient-years
RR = rate ratio
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2615L eft atrial appendage closure (LAAC) has beeninvestigated intensely for stroke preventionas an alternative to systemic oral anticoagula-
tion in selected patients with high-risk nonvalvular
atrial ﬁbrillation (NVAF) (1–11). The PROTECT AF (Pro-
spective Randomized Evaluation of the Watchman
LAA Closure Device In Patients With Atrial Fibrilla-
tion Versus Long Term Warfarin Therapy) trial was a
multicenter, randomized controlled trial in NVAF pa-
tients comparing the Watchman device to warfarin
for a composite primary endpoint of stroke, systemic
embolism, and cardiovascular (CV) death (1,9). Non-
inferiority to warfarin was documented early and
long term (2,621 patient-years [PY]), LAAC demon-
strated a signiﬁcant (40%) relative risk reduction to
warfarin for the primary efﬁcacy endpoint (1,5), an
85% relative risk reduction in hemorrhagic stroke, a
60% relative reduction in CV mortality (absolute
annual risk reduction of 1.4%), and a 34% relative
reduction in all-cause mortality (absolute annual
risk reduction of 1.6%) (5). Despite a positive vote
from the Center for Devices and Radiological Health
(CDRH) Panel in 2009, the U.S. Food and Drug Admin-
istration (FDA) issued a nonapprovable letter on the
basis of concerns of procedural complications, the
risk proﬁle of patients, and the confounding use and
effect of clopidogrel following implant. To address
these, the device manufacturer worked with
the FDA for a conﬁrmatory randomized trial (PRE-
VAIL [Prospective Randomized Evaluation of the
Watchman LAA Closure Device In Patients With Atrial
Fibrillation Versus Long Term Warfarin Therapy]
trial) comparing LAAC with the Watchman device to
warfarin, which mandated inclusion of new opera-
tors, slight modiﬁcations in inclusion criteria, and
elimination of clopidogrel 7 days before implant.
Bayesian statistical methodology was agreed upon
using informative prior data from the PROTECT AF
trial (see Methods section). At the pre-deﬁned evalu-
ation time point, the PREVAIL trial demonstrated
improved safety compared to the PROTECT AF trial,<25,000 V from Abbott, Access Closure, AGA, Angiomed, Aptus, Atrium,
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difference for post-procedure ischemic stroke
and systemic embolism. After review of these
data in December 2013, the FDA panel
returned a positive vote for safety, efﬁcacy,
and beneﬁt/risk. However, after this panel,
an updated data set to FDA as part of routine
regulatory ﬁlings raised further efﬁcacy con-
cerns, resulting in a third panel to evaluate
the totality of data.To evaluate the totality of data, this pa-
tient level meta-analysis was performed in
which: 1) all randomized patients from the
PROTECT AF and PREVAIL trials are combined and
the data analyzed using “traditional” frequentist
statistical methods; and 2) patients from 2 non-
randomized registries of LAAC with the device (the
CAP [Continued Access to PROTECT AF registry] and
the CAP2 [Continued Access to PREVAIL registry]) are
included. (3) By including these data from over 2,200
patients and w6,000 PY of follow-up, we provide the
most comprehensive assessment to date of the efﬁ-
cacy of Watchman LAAC for stroke prevention.
METHODS
Local institutional review board approval was ob-
tained for each dataset. All clinical trials were re-
gistered on ClinicalTrials.gov (1,3,4). The speciﬁc
Watchman device was identical throughout; a self-
expanding nitinol framed structure positioned at
LAA ostium with diameter ranges from 20 to 33 mm
and ﬁxation barbs to prevent embolization (9).
Implant protocols were identical. As previously
described (1,4,9), after implantation, patients were
treated with warfarin with an international normal-
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plete LAAC or if residual peridevice ﬂow was <5 mm
in width, warfarin was discontinued and the patient
was treated with clopidogrel 75 mg and aspirin 81 to
325 mg until 6 months following implantation, at
which time clopidogrel was discontinued and 325 mg
of aspirin was used indeﬁnitely. In the control
(warfarin) limb, INR was monitored every 2 weeks to
achieve an INR of 2 to 3. All patients had follow-up
visits at 45 days, and at 6, 9, and 12 months, and
then twice yearly.
All 4 datasets included a primary efﬁcacy com-
posite of all cause stroke (both hemorrhagic and
ischemic), systemic embolization, and CV death. Any
death of unknown origin was included as CV. Safety
endpoints varied slightly between the 2 randomized
trials and included bleeding as well as all cause stroke
(ischemic and hemorrhagic). To be a candidate for the
device, all patients had to be able to take warfarin for
45 days following implantation.
Because of the identical efﬁcacy endpoint deﬁni-
tions in both randomized trials, the data from both
trials were pooled for this meta-analysis (1,4).
PROTECT AF STUDY. Eligibility criteria included
$18 years of age with paroxysmal persistent or per-
manent AF with a CHADS2 risk score $1. Exclusion
criteria included absolute contraindications to
warfarin, LAA thrombus, a patent foramen ovale with
an atrial septal aneurysm and right to left shunt,
mobile aortic atheroma, or symptomatic carotid dis-
ease. The primary composite safety endpoint included
excessive bleeding or procedural-related complica-
tions (e.g., pericardial effusion requiring interven-
tion, device embolization, or procedural-related
stroke). A Bayesian statistical model (12) was used for
noninferiority trial design, and pre-speciﬁed endpoint
analysis of observed event rates after 600 follow-up
PY and after each additional 150 PY, up to 1,500.
PREVAIL TRIAL. Selection criteria were modiﬁed to
include higher risk patients: a CHADS2 score $2 or a
CHADS2 score $1 with more than 1 of the following
higher risk characteristics; female $75 years of age,
baseline ejection fraction $30% but <35%, 65 to
74 years of age with either diabetes or coronary artery
disease, and $65 years of age with heart failure. Ex-
clusion criteria were similar to the PROTECT AF trial,
except patients in whom clopidogrel therapy was
indicated were excluded because of the potential con-
founding inﬂuence of this drug on efﬁcacy outcome.
There were 3 coprimary endpoints: 1) a composite
efﬁcacy endpoint identical to the PROTECT AF
trial; 2) a second, “late ischemic efﬁcacy endpoint”— a
composite of ischemic stroke or systemic embolizationexcluding the ﬁrst 7 days post-randomization, which
aimed to isolate the mechanism of LAAC and its
potential effect on outcomes without the con-
founding inﬂuence of procedural complications;
and 3) a composite of early safety—death, ischemic
stroke, systemic embolization, device-/procedural-
related events requiring open CV surgery or a major
endovascular intervention between randomization
and 7 days post-procedure or during the index
hospitalization.
Inclusion of new operators was mandated to assess
procedural performance. Trial design recognized
the utility of the available efﬁcacy data from the
PROTECT AF trial, and used Bayesian statistical
methodology that allowed “borrowing” some data on
PREVAIL-eligible PROTECT AF trial patients at 1,500
PY of follow-up as an informative prior. Incorporation
of the informative prior allowed for a smaller conﬁr-
matory PREVAIL trial, but results in the fact that the
conﬁrmatory trial by itself is not powered to reach
robust conclusions. The PROTECT AF trial results
were combined with the small sample size of the
PREVAIL trial to conﬁrm device safety and collect
additional efﬁcacy data on LAAC. The resulting study
requirements were such that follow-up with the new
PREVAIL trial patients was limited to 6 months min-
imum in order for the endpoint to occur using the
modeled 18-month event rates against pre-speciﬁed
performance boundaries.
REGISTRIES. The registries (3) were designed to treat
patients with similar baseline characteristics ac-
cording to the same protocols after the speciﬁc trial
enrollment had been completed—CAP following
PROTECT AF and CAP2 following the PREVAIL trial.
Procedural performance and adjunctive medications
were identical in each registry and the respective
randomized trials except registries did not mandate
1-year neurological assessment required in both
randomized trials.
DEFINITIONS. For all data sets, the CHADS2 score
(1,4) was used for patient entry. Because the
CHA2DS2-VASc score has largely supplanted CHADS2
(13–16), risk prediction was reported using both.
Assessment of bleeding risk was a clinical site deter-
mination. Though not prospectively captured in
the Watchman studies, many components of the
HAS-BLED (13,15) score were captured as a part of
routine data collection. A conservative bleeding score
was determined using the available case report form
data and points were assigned per the HAS-BLED
score. Abnormal liver function and labile INR were
not captured and were consequently assigned a score
of zero. An independent Clinical Events Committee
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Ischemic stroke was deﬁned as sudden onset of a
focal neurological deﬁcit with symptoms and/or signs
persisting >24 h, or symptoms <24 h with computed
tomography or magnetic resonance imaging evidence
of tissue loss without hemorrhage. Although hemor-
rhagic stroke deﬁnitions varied slightly from the
PROTECT AF trial to the PREVAIL trial, they included
sudden onset of a focal neurological deﬁcit with
computed tomography or magnetic resonance imag-
ing evidence of tissue loss with evidence of blood
vessel and/or intracranial hemorrhage with symp-
tomatic focal neurological deﬁcit. Subdural hema-
tomas with evidence of parenchymal involvement
such as parenchymal extensions or contusion were
adjudicated as a hemorrhagic stroke, unless conﬁned
exclusively to the subdural space.
STATISTICAL ANALYSIS FOR META-ANALYSIS. This
patient level meta-analysis had 3 components: 1) as-
sessment of the device outcomes including all primary
efﬁcacy components, all-cause mortality, and major
bleeding versus warfarin control in patients random-
ized in both the PROTECT AF and PREVAIL trials; 2)
the primary composite efﬁcacy rates of patients
receiving the Watchman device in both randomized
controlled trials and registries; and 3) comparison of
the device performance in each of the 4 trials.
Both randomized trials were designed to establish
noninferiority of a device-based strategy versus
warfarin for a composite primary efﬁcacy endpoint.
To evaluate beneﬁt-risk ratio, the PROTECT AF and
PREVAIL data sets were combined with all available
follow-up and analyzed as a traditional patient-level
meta-analysis. Fully utilizing the data from both tri-
als while accounting for the fact that they are
different studies facilitates more robust exploration
of the role of covariates.
This meta-analysis of these 2 studies is appropriate
because both studies randomized subjects to the same
treatment strategies (Watchman vs. warfarin) and
primary efﬁcacy endpoint deﬁnitions. The baseline
risk proﬁle in the combined the PROTECT AF and
PREVAIL trial population included a somewhat higher
risk proﬁle for the PREVAIL trial; subgroup analyses by
CHADS2 and CHA2DS2-VASc scores were performed to
assess differences in outcome by baseline risk proﬁle.
Further, results were stratiﬁed with Cox proportional
hazards modeling, adjusting for potential baseline risk
differences. In addition, the device patients from the
registry data were combined with all randomized data
in the same fashion. Though registries had no control
group, the same criteria around device and primary
efﬁcacy deﬁnitions apply. Given the variable initiationof recruitment, the PROTECT AF trial patients have
the longest follow-up, but registry patients provide
the largest number of patients.
Analyses were intent-to-treat, censoring data from
patients without events at the time of the last
known status. A Cox proportional hazards model with
conﬁdence intervals (CIs) was used for comparison
of event rates. For the analysis including the ran-
domized trials, this model was stratiﬁed by study
(PROTECT AF or PREVAIL) in order to account for
differences in risk proﬁles. For the analysis including
all 4 data sets, studies were treated as “clusters” in
order to account for correlation among patients
within studies. The Kaplan-Meier method was used
for graphical assessment of time-dependent events.
Results are presented using frequentist statistics and
2-sided p values nominally signiﬁcant at p < 0.05
with no adjustments for multiple comparisons.
RESULTS
PATIENT CHARACTERISTICS. Four clinical trials
enrolled 2,406 patients from 2005 to 2014; 1,877 were
treated with Watchman (1,145 Registry patients) and
382 (the control limbs in the 2 randomized clinical tri-
als) received warfarin. Mean follow-up depended on
when the patients were enrolled; there were a total of
5,931 PY follow-up available (Table 1). Patient follow-
up for CAP2 was the shortest by virtue of enrollment
initiation (mean follow-up of 0.58 years vs. 4.0 for the
PROTECT AF trial and 3.7 years for CAP). There was a
progressive increase in patient risk over the course of
these data sets (Table 2); mean patient age ranged from
72.0  8.9 years of age in the PROTECT AF trial to
75.3  8.0 years of age in CAP2. The CHADS2 score
similarly ranged from 2.2  1.2 to 2.7  1.1 (p < 0.0001)
as did the CHA2DS2-VASc score 3.5  1.6 to 4.5  1.3
(p < 0.0001). On the basis of these scores, the total
predicted annualized risk for stroke, if untreated with
anticoagulation, ranged from 5.7% to 7.6% annually.
The distribution of both CHADS2 and CHA2DS2-
VASc scores documented the majority of patients
were high risk for stroke and all were eligible for
warfarin (Figures 1A and 1B). Conversely, 90% of pa-
tients were moderate to high risk of bleeding using
the estimated HAS-BLED score; 61% had a moderate
risk of increased bleeding. The PROTECT AF trial had
the highest prevalence of a low-risk HAS-BLED score,
but even in this study, this only constituted 6.4% of
the study. Between 93.2% and 98.7% of patients were
able to discontinue warfarin at 1 year.
LAAC VERSUS WARFARIN—META-ANALYSIS OF
RANDOMIZED CLINICAL TRIALS. Both the PROTECT
AF and PREVAIL trials shared the primary efﬁcacy
TABLE 2 Patient De
Age, yrs
Male
Ethnicity/race
Asian
Black/African Americ
White/Caucasian
Hispanic/Latino
Other
CHADS2 score
CHADS2 risk factors
CHF
Hypertension
$75 yrs of age
Diabetes
Stroke/transient
ischemic attack
CHA2DS2-VASc
HAS-BLED ¼ 0 (low ris
HAS-BLED ¼ 1–2 (mod
HAS-BLED ¼ 3þ (high
Values are mean  SD or %
CHF ¼ congestive heart
TABLE 1 PROTECT AF and CAP: Largest Data Sets to Evaluate Totality of Data
PROTECT AF PREVAIL CAP CAP2 Total
Enrollment 2005–2008 2010–2012 2008–2010 2012–2014
Enrolled 800 461 566 579 2,406
Randomized 707 407 — — 1,114
Watchman:warfarin (2:1) 463:244 269:138 566 579 1,877:382
Mean follow-up, yrs 4.0 2.2 3.7 0.58 N/A
Patient-years 2,717 860 2,022 332 5,931
CAP ¼ Continued Access to PROTECT AF registry; CAP2 ¼ Continued Access to PREVAIL registry; N/A ¼ not
applicable; PREVAIL ¼ Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With
Atrial Fibrillation Versus Long Term Warfarin Therapy; PROTECT AF ¼ Watchman Left Atrial Appendage System
for Embolic Protection in Patients with Atrial Fibrillation.
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The meta-analysis of the randomized clinical trial co-
horts reveals that the hazard ratio (HR) for this com-
posite efﬁcacy endpoint was 0.79 (95% CI: 0.53 to 1.2;
p ¼ 0.22) (Figure 2) meeting noninferiority of LAAC
versus warfarin. Event rates per 100 PY were 2.72 (95%
CI: 2.29 to 3.24) and 3.50 (95% CI: 2.60 to 4.72) for de-
vice and warfarin, respectively. But for the individual
endpoint components, there were signiﬁcant differ-
ences. Although all-cause stroke or systemic embolism
rates per 100 PY were virtually identical between the 2
strategies (device: 1.75; 95% CI: 1.41 to 2.17; warfarin:
1.87; 95% CI: 1.41 to 2.17; HR: 1.02; 95% CI: 0.62 to 1.7;
p ¼ 0.94), there were differences when strokes were
subdivided into ischemic versus hemorrhagic. Though
there were more ischemic strokes in the device groupmographics Across Trials
PROTECT AF
(N ¼ 707)
PREVAIL
(N ¼ 407)
CAP
(N ¼ 566)
CAP2
(N ¼ 579)
72.0  8.9 74.3  7.4 74.0  8.3 75.3  8.0
70.3 70.0 65.5 61.0
0.7 0.5 1.6 0.7
an 1.6 1.7 1.9 1.2
91.5 94.4 91.9 94.1
5.7 2.7 3.5 2.1
0.6 0.7 1.1 1.0
2.2  1.2 2.6  1.0 2.4  1.2 2.7  1.1
26.9 19.1 23.3 27.1
89.8 88.8 91.4 92.5
43.1 51.8 53.6 59.7
26.2 24.9 32.4 33.7
18.5 30.4 27.8 29.0
3.5  1.6 4.0  1.2 3.9  1.5 4.5  1.3
k) 6.4 1.7 2.8 2.8
erate risk) 73.7 68.6 61.0 69.9
risk) 19.9 29.7 36.2 28.3
.
failure; other abbreviations as in Table 1.(1.6 vs. 0.9 events/100 PY; HR: 1.95; p ¼ 0.05) once
procedure-related strokes were excluded, the rates of
ischemic stroke were no longer signiﬁcantly different
between the device and warfarin (HR: 1.40 [95% CI:
1.10 to 1.78] and HR: 0.89 [95% CI: 0.50 to 1.61];
HR: 1.56; 95% CI: 0.78 to 3.09; p ¼ 0.21). In contrast,
hemorrhagic stroke occurred signiﬁcantly less
frequently in the LAAC treated patients at a rate of 0.15
per 100 PY (95% CI: 0.07 to 0.4) for device versus 0.96
(95% CI: 0.55 to 1.70) for warfarin (HR: 0.22; 95% CI:
0.08 to 0.61; p ¼ 0.004). There were also signiﬁcantly
fewer CV deaths in the LAAC cohort (HR: 0.48; 95% CI:
0.28 to 0.81; p ¼ 0.006).
Subgroup analysis of the composite efﬁcacy
endpoint revealed no signiﬁcant interaction with cli-
nical characteristics such as age dichotomized at
75 years of age, sex, or the CHADS2 and CHA2DS2-
VASc risk scores (Figure 3). The p value for interaction
of the estimated HAS-BLED score was 0.098. Finally,
the presence or absence of a history of transient
ischemic attack or stroke before entering the clinical
trial also failed to affect outcomes.
Beyond the composite efﬁcacy endpoint and its
individual components, 2 additional analyses were
performed: all-cause mortality and major bleeding
(Figure 2). Consistent with CV mortality, the HR for
all-cause mortality also favored LAAC, but did not
reach statistical signiﬁcance (HR: 0.73; 95% CI: 0.52 to
1.00; p ¼ 0.07). For total major bleeding including the
index implantation period, there was no signiﬁcant
difference between LAAC and warfarin (HR: 1.00;
95% CI: 0.69 to 1.40; p ¼ 0.95). However, for non–
procedure-related major bleeding occurring after the
ﬁrst 7 days post-implantation, there was a highly
signiﬁcant reduction in events in the LAAC arm
(HR: 0.51; 95% CI: 0.33 to 0.77; p ¼ 0.02).
LAAC VERSUS WARFARIN: META-ANALYSIS OF
RANDOMIZED CLINICAL TRIALS AND NONRANDOMIZED
REGISTRIES. In addition to 732 and 382 patients ran-
domized to either LAAC or warfarin, respectively, the
2 registries enrolled 1,145 patients undergoing
Watchman implantation. Despite the fact that the
average risk score for the patients in the registries
was higher than that of the patients enrolled in the 2
randomized clinical trials, the composite efﬁcacy
event rates were consistent. Kaplan-Meier analysis
revealed similar rates of events between the LAAC
arms of the randomized clinical trials and registry
patients (Central Illustration), even though the latter
had higher baseline risk. The meta-analysis of all
4 clinical trials was entirely consistent with the
balanced comparison of the randomized clinical trials
alone: 1) the overall composite efﬁcacy endpoint was
similar between groups; 2) the increase in ischemic
FIGURE 1 Majority of Watchman Patients at High Risk of Stroke and
Moderate-to-High Bleeding Risk
50%
Anticoagulation Eligible
High Risk
40%
Patients
(%)
Patients
(%)
A
B
30%
20%
10%
0%
100%
PROTECT AF
CAP
PREVAIL
CAP2
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
0 1–2
HAS BLED Score
3+
1 2 3
CHA2DS2-VASc Score
CHA2DS2-VASc
Score ≥2
93%
96%
100%
100%
4 5 6–9
(A)Themajority ofWatchmanpatients are high risk. CHA2DS2-VASc score is increasingly used
toestimate stroke risk inpatientswithnonvalvular atrialﬁbrillation. In all 4data sets, patients
were at increased risk for stroke per American College of Cardiology/American Heart Asso-
ciation/Heart Rhythm Society (ACC/AHA/HRS) 2014 guidelines, particularly in the PREVAIL
(Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With
Atrial Fibrillation Versus Long TermWarfarin Therapy) trial andContinuedAccess to PREVAIL
registry. (B)Most Watchman patients have moderate to high HAS-BLED scores. Patients
in all 4 data sets also had increased risk of bleeding. CAP ¼ Continued Access to PROTECT
AF registry; CAP2 ¼ Continued Access to PREVAIL registry; PROTECT AF ¼Watchman
Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation.
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2619stroke seen in the LAAC group is counterbalanced by
a highly signiﬁcant reduction in hemorrhagic stroke;
3) there were signiﬁcantly fewer CV deaths with
LAAC; 4) all-cause mortality favored LAAC, but was
not statistically signiﬁcant; and 5) major bleeding was
similar between groups, but non–procedure-related
bleeds occurred with signiﬁcantly greater frequency
with warfarin treatment.
DISCUSSION
In patients with NVAF, the totality of the Watchman
data from 2 randomized clinical trials and 2 non-
randomized registries demonstrates: 1) local therapy
with LAAC provides similar beneﬁt to warfarin for the
composite efﬁcacy endpoint of stroke, systemic em-
bolism, or CV death; 2) compared with long-term
warfarin, patients randomized to LAAC have a sig-
niﬁcant improvement in survival, particularly
freedom from CV death; 3) although all-cause stroke
rates are identical between groups, the pathophysi-
ology of stroke was signiﬁcantly different; more
warfarin patients experiencing hemorrhagic strokes
and more device patients experiencing ischemic
strokes; 4) by 1 year, approximately 95% of device
patients discontinued warfarin; 5) although all-cause
bleeding was similar between groups, when peri-
procedural bleeding was excluded, bleeding rates
were signiﬁcantly higher in patients treated with
chronic warfarin; 6) device performance was consis-
tent over the entire data set—both randomized clin-
ical trials and registries, the latter of which are likely
to more closely resemble real world experience.
The relationship between the increasing incidence
of NVAF and consequent stroke is well described:
stroke rates are increased 4- to 5-fold, larger and more
debilitating with hemorrhagic conversion, and higher
recurrence rates (13,17–20). In patients >80 years of
age, AF is believed to be responsible for 15% to 30% of
strokes (20). Although warfarin has been the mainstay
for stroke prevention, reducing it by approximately
65%, its disadvantages are well appreciated including
drug-drug interactions, the need for frequent moni-
toring and dose adjustment, and the potential for
bleeding. In addition, when a stroke occurs in the
setting of anticoagulant therapy, mortality rates
approximate 50%. In the National Electronic Injury
Surveillance System project that included 99,682
emergency hospitalizations, warfarin was the most
commonly implicated medication, constituting 33%
of cases (21). Combined with the anxiety provoked by
the fear of bleeding, these reasons have led to the fact
that over 40% of patients with NVAF at risk for stroke
do not receive warfarin, either because of absolute orrelative contraindications, as perceived by patients or
physicians (10,13,22–24).
Warfarin limitations have led to the development
of new oral anticoagulant agents (NOACs), such as
Factor II and Xa inhibitors, which have now been
studied in comparison to warfarin in large randomized
trials (25–30). In a meta-analysis of trials randomizing
NOACs to warfarin, NOACs were associated with a
signiﬁcant decrease in stroke (RR: 0.81; 95% CI: 0.73 to
0.91), primarily driven by a reduction in hemorrhagic
stroke (RR: 0.48; 95% CI: 0.39 to 0.59). There was also
a signiﬁcant decrease in all-cause mortality (RR: 0.90;
95% CI: 0.85 to 0.95), but a signiﬁcant increase in
gastrointestinal bleeding (RR: 1.25; 95% CI: 1.01 to
FIGURE 2 PROTECT AF/PREVAIL Combined: Meta-Analysis Shows Comparable
Primary Efﬁcacy Results to Warfarin
Efficacy
HR p Value
All stroke or SE
Ischemic stroke or SE
0.79
1.02
1.95
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0.48
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1.00
0.51
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0.004
0.21
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Major bleeding, non procedure-related
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Hazard Ratio (95% Cl)
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Favors Watchman Favors warfarin
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The combined data set of all PROTECT AF and PREVAIL Watchman patients versus chronic
warfarin patients documented: 1) similarity in overall stroke or systemic embolism;
2) ischemic stroke slightly increased with Watchman but hemorrhagic stroke signiﬁcantly
decreased with warfarin; and 3) all-cause mortality and major nonprocedural bleeding both
signiﬁcantly improved with Watchman. CI ¼ conﬁdence interval; CV ¼ cardiovascular;
HR ¼ hazard ratio; SE ¼ systemic embolism; other abbreviations as in Figure 1.
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26201.55) (30). These new agents have not become domi-
nant in the ﬁeld of stroke prevention for several rea-
sons, including cost, lack of antidotes, need for twice
daily dosing (with 2 of the agents), and side effects. In
addition, by 2 years, 21% to 33% of patients dis-
continued the NOAC, and the major bleeding rate per
year was 2 to 3.5%, both of which are similar to that
reported for conventional warfarin (26–28).Watchman Efﬁcacy Performance in Randomized Clinical Trials
AIL)
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There was no signiﬁcant difference in Watchman effect by patient
nt ischemic attack; other abbreviations as in Figure 1.The LAA has been implicated as the source of
emboli in w90% of patients with NVAF (7); strategies
to isolate or occlude the LAA have been developed
with initial studies demonstrating feasibility and
safety. LACC may have competing inﬂuences on
stroke rates: on the one hand, local therapy with LAAC
would not attenuate stroke arising from other vascular
sources such as aortic atheroma or carotid disease, but
on the other hand, truncating exposure to anticoagu-
lant agents should minimize the risk for hemorrhagic
complications, including stroke. To evaluate the risk/
beneﬁt ratio of local therapy, the PROTECT AF and
PREVAIL trials were performed. Taken together, the 2
randomized trials included 1,114 randomized patients
with 3,577 PY of follow-up. By virtue of trial enroll-
ment dates, the PROTECT AF data represents 75% of
all of the available follow-up. Although not dictated by
trial design, the majority of patients enrolled in these
trials were at moderate to high risk for bleeding on the
basis of the estimated HAS-BLED score.
For this meta-analysis of the randomized clinical
trials, the composite efﬁcacy endpoint favored the
Watchman patients (HR: 0.79), albeit without reaching
statistical signiﬁcance (p ¼ 0.22). The individual com-
ponents of this composite endpoint, however, were
quite different between groups. The 3 most striking
differences were in hemorrhagic stroke (HR: 0.22;
p ¼ 0.004), CV/unexplained death (HR: 0.48;
p ¼ 0.006), and major non–procedural-related
bleeding (HR: 0.51; p ¼ 0.002). The reduction in hem-
orrhagic stroke and major nonprocedural bleeding
could have been anticipated because device patients
were not chronically exposed to a continued incre-
mental bleeding risk from anticoagulation. Between
93.2% and 98.7% of patients had been able to discon-
tinue warfarin after 1 year.
The reduction in hemorrhagic stroke with LAACwas
balanced by a relative increase in ischemic stroke or
systemic embolism with rates per 100 years for device
and warfarin of 0.15 and 0.96 (hemorrhagic), respec-
tively, and 1.62 and 0.89 (ischemic, including proce-
dure related), respectively. As mentioned this may
relate to the fundamental observation that local device
therapy does not prevent strokes from other causes.
Alternatively, the higher ischemic stroke rate may
relate to possible technical failures of the device: fail-
ure to completely obliterate LAA ﬂow, anatomical
remodeling of the LAA ostium over time resulting in
more leaks, or the development of thrombus on the
device. Although small series have raised questions
about the embolic potential of these small leaks
(<5 mm), the only large patient dataset evaluated to
address this question indicated that small residual
leaks are not associatedwith increased stroke rates (31).
CENTRAL ILLUSTRATION Stroke Prevention in Nonvalvular Atrial Fibrillation With LAA Closure
Holmes, Jr., D.R. et al. J Am Coll Cardiol. 2015; 65(24):2614–23.
(Upper Panel) Combination of PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) and PREVAIL (Pro-
spective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) trial patients receiving the
Watchman device, compared with patients receiving chronic warfarin for overall stroke, ischemic stroke, and all-cause death. (Bottom Panel) Watchman performance
consistent across all 4 data sets. Although the duration of follow-up varied by trial enrollment periods, being shortest for the Continued Access to PREVAIL registry
(CAP2), overall freedom from event was similar in all 4 groups treated with Watchman. CAP ¼ Continued Access to PROTECT AF registry; CI ¼ conﬁdence interval; CV ¼
cardiovascular; HR ¼ hazard ratio; LAA ¼ left atrial appendage; SE ¼ systemic embolism.
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2621The dramatic reduction in CV/unexplained death
withWatchman (HR: 0.48; p¼0.006) is one of themost
signiﬁcant ﬁndings. This mortality beneﬁt may be
multifactorial, but is likely at least in part a result of
the reduced rate of hemorrhagic stroke and is
completely consistent with thew10% to 15%mortality
beneﬁt that NOACs confer over warfarin—a beneﬁt
also driven by the reduction in hemorrhagic stroke
with NOACs (26–28). However, it should also be noted
that the PROTECT AF and PREVAIL trial patients had
multiple comorbidities. In this setting, one cannot ruleout the possibility that a small amount of bleeding in a
warfarin-treated patient could have had signiﬁcant
clinical implications, or resulted in discontinuation of
other beneﬁcial medications because of postulated
drug-drug interactions. Also, some of the deaths in
the warfarin arm may have resulted from undetected
ischemic stroke with hemorrhagic transformation.
The addition of the CAP and CAP2 registries to the
meta-analysis added important information to the to-
tality of the Watchman data. In these registries, 1,145
patients were enrolled and the procedural performance
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Car-
dioembolic strokes in patients with nonvalvular atrial
ﬁbrillation typically arise from the left atrial
appendage, and are associated with high rates of
recurrence, morbidity, and mortality. Although sys-
temic anticoagulation can reduce the risk of stroke in
patients with atrial ﬁbrillation, this form of therapy
carries a risk of bleeding and a large proportion of
patients are undertreated.
COMPETENCY INPATIENTCAREANDPROCEDURAL
SKILLS: In patients at elevated risk of stroke and
bleeding with suitable anatomy, occlusion of the left
atrial appendage with the catheter-deployed
Watchman device is associated with lower risks of
major bleeding post procedure, hemorrhagic stroke,
and mortality than long-term warfarin therapy.
TRANSLATIONAL OUTLOOK: Further studies are
needed to deﬁne risk thresholds for thromboembo-
lism and bleeding at which patients with atrial ﬁbril-
lation beneﬁt from left atrial appendage occlusion
therapy for stroke prevention and to compare the
safety and efﬁcacy of this strategy with target-
speciﬁc oral anticoagulant agents.
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2622and follow-up schedules were similar. The absence of
trial randomization in these registries was associated
with a patient cohort at somewhat higher risk for both
stroke and hemorrhage. Although a warfarin control
cohort for the registries was also not available for in-
clusion into the meta-analysis, this additional bias fa-
voring the warfarin group did not appreciably alter any
of the conclusions derived from the randomized cli-
nical trial—alonemeta-analysis. The LAAC andwarfarin
groups performed similarly for the composite efﬁcacy
endpoint; the advantage seen with warfarin for is-
chemic stroke was counterbalanced by improved rates
of hemorrhagic stroke and CV death with LAAC, and
major non–procedure-related bleeding was signiﬁ-
cantly less frequent with LAAC. Thus, device perfor-
mance was consistent across all 4 clinical trial datasets.
An important consideration revolves around pa-
tient selection criteria. With that in mind, the risk
beneﬁt of an invasive procedure must be balanced
against the longer term issues of continued exposure
to anticoagulation and bleeding. In patients who are
excellent candidates for an anticoagulant agent, or
who have uncomplicated success with anticoagulant
agents for stroke prevention, an LAAC device may not
be needed. In other patients, careful consideration of
LAAC versus long-term anticoagulant agents warrants
an individualized discussion between physician and
patient.
STUDY LIMITATIONS. There are important considera-
tions that these analyses do not address. By trial
design, all device patients were treated with aspirin
and warfarin until the 45 day transesophageal echo-
cardiogram, and thereafter acetylsalicylic acid and
Plavix for 6 months followed by acetylsalicylic acid
alone. An important question relates to the population
of “contraindicated” patients, those with NVAF at risk
of stroke but who are either not prescribed, or do not
take, oral anticoagulation. Although all 4 Watchman
studies excluded these contraindicated patients, in the
Aspirin Plavix Registry (8), the devicewas implanted in
150 NVAF patients ineligible for warfarin. As compared
to the expected stroke rates in this population, there
were 77% fewer ischemic strokes observedwith device.
Another question not answered by these analyses is
the relative effect of the device compared to currently
approved NOACs. Currently, there are no data com-
paring LAAC to any of the NOACs. It must be remem-
bered that even in the randomized NOAC trials, the
2-year drug discontinuation rates ranged between
21% and 33%, and for these patients, the protective
effect of the drug would accordingly be lost (26–28).
Though warfarin has been extensively studied and
has well-characterized efﬁcacy rates, it should benoted that the Watchman trials were randomized in a
2-to-1 fashion, thus resulting in a limited number of
warfarin patients with whom to compare the device,
and the majority of device patients in this analysis
(62%) were registry patients.
CONCLUSIONS
In the setting of NVAF with increased stroke risk,
systemic embolism, or CV death, patients who are
treated with the Watchman device for LAAC have
marked reduction in hemorrhagic stroke, CV death,
and major non–procedural-related bleeding compared
to patients treated with chronic warfarin. This is
balanced by a smaller magnitude increase in ischemic
stroke in device treated patients that may reﬂect the
diverse etiology of stroke in this population.
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